Evidence map›Paper›PMID 42321543›Full record

ArticleEuropean journal of nuclear medicine and molecular imaging2026

Dopaminergic nigrostriatal vulnerability in Parkinson's Disease with diabetes: evidence from severity-matched cohorts.

Alice Galli, Cinzia Zatti, Alessandro Lupini, Silvia Paola Caminiti, Andrea Rizzardi, Silvia Lucchini, Francesco Bertagna, Barbara Paghera, Tiago Fleming Outeiro, Daniela Perani and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European journal of nuclear medicine and molecular imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Alice GalliNeurology Unit, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, 25123, Italy.
Cinzia ZattiNeurology Unit, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, 25123, Italy.
Alessandro LupiniNeurology Unit, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, 25123, Italy.
Silvia Paola CaminitiDepartment of Brain and Behavioral Sciences, University of Pavia, Pavia, Italy.
Andrea RizzardiNeurology Unit, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, 25123, Italy.
Silvia LucchiniNuclear Medicine Unit, University of Brescia, Brescia, 25123, Italy.
Francesco BertagnaNuclear Medicine Unit, University of Brescia, Brescia, 25123, Italy.
Barbara PagheraNuclear Medicine Unit, University of Brescia, Brescia, 25123, Italy.
Tiago Fleming OuteiroDepartment of Experimental Neurodegeneration, University Medical Center Goettingen, Goettingen, Germany.
Daniela PeraniVita Salute San-Raffaele University, Milan, 20123, Italy.
Alessandro PadovaniNeurology Unit, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, 25123, Italy.
Andrea PilottoNeurology Unit, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, 25123, Italy. pilottoandreae@gmail.com.ORCID 0000-0003-2029-6606

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeDiabetes Mellitus (DM) has been recognized as a potential risk factor and disease-modifier in Parkinson's Disease (PD), being associated with worse motor and cognitive outcomes, and altered susceptibility of neural pathways. This study investigated the impact of DM on nigrostriatal dopaminergic vulnerability independently of disease severity in drug-naïve PD patients.

methodsThis study analyzed two independent cohorts of PD patients (multi-center PPMI n = 174, single-center UniBS n = 95). Patients with and without DM were first compared and then matched for age, sex, and clinical severity. All patients underwent baseline

resultsPatients with DM were older, predominantly male, and exhibited worse non-motor and cognitive symptoms. After severity matching, PD-DM exhibited more preserved nigrostriatal dopamine uptake compared to PD-n. PD-DM also showed fewer nigrostriatal dopaminergic connectivity alterations (10% vs. 21%) and reduced neural reserve index in the left putamen and - only in the single-center cohort- whole striatum.

conclusionIn drug-naïve PD patients, comorbid diabetes is associated with comparable clinical severity despite milder dopaminergic loss. This suggests an increased dopamine system vulnerability linked to DM, reducing the efficiency and compensatory mechanisms of nigrostriatal dopaminergic networks in PD.

Indexed as

Corpus StriatumDiabetes MellitusDopamineParkinson DiseaseSubstantia NigraAgedCohort StudiesDopamine Plasma Membrane Transport ProteinsDopaminergic ImagingFemaleHumansMaleMiddle AgedSeverity of Illness IndexTropanes2-carbomethoxy-8-(3-fluoropropyl)-3-(4-iodophenyl)tropaneDopamineDopamine Plasma Membrane Transport ProteinsTropanesDiabetes mellitusDopamine transporter imagingNigrostriatal pathwayParkinson’s disease

Identifiers

PMID42321543
PMCPMC13526104

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.